Skip to content

Basket

You currently have no items in your basket.

Total (excl. vat) £0.00
View basket & checkout

Human Cytokine Products

1. Highly Active Human Interferon Protein

High quality recombinant proteins derived from bacterial or mammalian cells

  • Consistent performance and biological activity
  • 95% or greater purity
  • Endotoxin level < 1 EU/μg
  • Suitable for use in a range of applications including ELISAs & cytopathic effect assays


Key Benefits of PBLs IFN Elisa Kits are: 

  • Best in class kits that support different research needs 
  • Extensively used as they are highly sensitive and can detect the lowest levels if IFN subunits 
  • Validated by many CROs and has been development by testing with diseased samples 
  • Can detect the lowest level of LLOQ all disease sample matrix therefore robust matrix tolerance 

Featured:
Universal Type I Interferon (Cat. No. 11200)
Unique hybrid interferon exhibiting activity across multiple species

  • Useful for cross-species comparative studies of Type I IFN effects
  • Broad crossover to multiple animal models in vivo and in vitro where the species relevant Type I IFN-α is unavailable or performs inconsistently
  • High specific activity on multiple animal cell lines

Comparison of the Activities of Universal Type I IFN, Human IFN Alpha 2a, and Mouse IFN Alpha AFigure 1. Comparison of the Activities of Universal Type I IFN, Human IFN Alpha 2a, and Mouse IFN Alpha A

2. Human Interferon Alpha (IFN-α) ELISAs

Featured:
Human IFN Alpha All Subtype ELISA (Cat. No. 41115)
High Sensitivity – can detect lowest level of subunits 

  • Assay Standard Range: 1.95 – 125 pg/ml
  • Accurate low pg/ml detection of all human IFN-α subtypes
  • Robust matrix tolerance including autoimmune disease sera, normal serum, and tissue culture media (TCM)
  • Optimized for autoimmune serum and plasma samples
  • Consistent, reproducible results with < 10% inter- and < 8% intra-assay CVs
  • Detects previously “missed” IFN-α subtypes



Figure 2. IFN-α Specific Signal in Lupus Patients. Lupus patient serum number. Purple bars represent non-specific signal, i.e., signal not blocked by AntiIFN-α PAb.Figure 2. IFN-α Specific Signal in Lupus Patients. Lupus patient serum number. Purple bars represent non-specific signal, i.e., signal not blocked by AntiIFN-α PAb.

Table 1. Lower Limit of Quantitation (LLOQ) and Lower Limit of Detection (LLOD) in Normal Human Serum for all 12 IFN Alpha subunits including a Absorbance Chart at 450nm 

SubtypeLLOQ (pg/ml)LLOD (pg/ml)

α1 (αD)

2.31

0.76

α2a (αA)

1.36

0.42

α4a (αM1)

1.38

0.43

α5 (αG)

1.70

0.51

α6 (αK)

1.13

0.33

α7 (αJ1)

2.09

0.59

α8 (αB2)

2.81

0.82

α10 (αC)

1.77

0.65

α14 (αH)

1.76

0.51

α16 (αWA)

2.01

0.68

α17 (αI)

1.36

0.50

α21 (αF)

6.18

1.67


● Good   ● ● Better   ● ● ● Best
Global IFN-α subtype measurement in serum or plasma
 
 
● ●
● ● ●
Global IFN-α subtype measurement in TCM
 
● ●
● ●
● ● ●
Reproducible results with < 10% inter- & intra-assay CVs
● ● ●
● ● ●
● ● ●
● ● ●


3.Human Interferon Beta (IFN-β) ELISAs

Featured:
Human IFN Beta Serum ELISA (Cat. No. 41415)
High Sensitivity

  • Assay Standard Range: 1.2 – 150 pg/ml
  • Provides > 90% serum spike-recovery
  • Reproducible results with < 8% inter- and intra-assay CVs
  • Robust matrix tolerance for autoimmune disease sera
  • Validated by multiple CROs for sensitive measurement of IFN-β therapeutics in human serum samples
  • e.g. Rebif®, Avonex®, Extavia®, Betaseron®
  • Suitable for PK, PD, Toxicity & Biomarker studies
Figure 3. ELISA Standard Curve in Normal Human Serum (NHS) vs. Standard Curve in Standard Diluent. No observable inhibitory effect of normal human serum.
Figure 3. ELISA Standard Curve in Normal Human Serum (NHS) vs. Standard Curve in Standard Diluent. No observable inhibitory effect of normal human serum.
Figure 4. Multiple Sclerosis (MS). IFN-β was measured in sera/plasma of Multiple Sclerosis (MS) patients and Normal Donors. IFN-β was found to be quantifiable in 86% of MS patients on IFN-β therapy, 4.1% of MS patients on other therapies, and 1.5% of Normal Donor samples
Figure 4. Multiple Sclerosis (MS). IFN-β was measured in sera/plasma of Multiple Sclerosis (MS) patients and Normal Donors. IFN-β was found to be quantifiable in 86% of MS patients on IFN-β therapy, 4.1% of MS patients on other therapies, and 1.5% of Normal Donor samples

Related Products

To learn more, please contact Info@2BScientific.com or call us at +44 (0)1869 238033!

 
● Good   ● ● Better   ● ● ● Best
Accurate IFN-β measurement in serum or plasma (including autoimmune disease sera)
 
● ● ●
Accurate IFN-β measurement in tissue culture media (TCM)
● ●
● ● ●
Reproducible results with < 10% inter- & intra-assay CVs
● ●
● ● ●

4. Anti-Human IFN Monoclonal (MAb) & Polyclonal (PAb) Antibodies

Labeled & unlabeled antibodies for a variety of uses

  • MAbs offer high specificity in applications where specific binding is desirable
  • PAbs are preferable for neutralization because they target a variety of specific epitopes of a particular antigen

Featured: Anti-Human IFNAR2, Clone MMHAR-2 (MAb) (Cat. No. 21385-1)

  • Blocks biological activity of human Type I IFNs and IFN-α receptor.
  • Binds to human IFN-α receptor with high affinity.

Figure 5. Mouse MAb to Human IFN-Alpha/Beta Receptor 2.

Figure 5. Mouse MAb to Human IFN-Alpha/Beta Receptor 2.

Human Type I IFN Neutralizing Antibody Mixture (Cat. No. 39000)
Mixture of MAbs and PAbs directed against human Type I IFNs & IFNAR2

  • Effectively neutralizes biological activity of human IFN-α, IFN-β, IFN-ω, IFN-κ, and IFN-ε.
  • Improves neutralization of multiple Type I IFNs often found in complex samples by employing a broadly neutralizing custom antibody cocktail.

Figure 6. Representative neutralization curves (diluted 1:50) to human IFN-α, -β, and -ω. A549 cells incbated with antibody mixture and titrated IFN, subsequently challenged with EMCV.

Figure 6. Representative neutralization curves (diluted 1:50) to human IFN-α, -β, and -ω. A549 cells incbated with antibody mixture and titrated IFN, subsequently challenged with EMCV.